Mar, 2021

U.S.A.
News / Corporate
Astellas Oncology Announces Grand Prize Winner of Fifth Annual C³ Prize® Challenge
Astellas Pharma US, Inc. ("Astellas") today announced the Grand Prize winner and two Innovation Prize winners for the fifth annual Astellas Oncology C3 Prize (Changing Cancer Care), a global...
Read More

Feb, 2021

U.S.A.
News / Corporate
Astellas expands Top Management, names Percival Barretto-Ko as Chief Business Officer; Yoshitsugu Shitaka as Chief Scientific Officer
Astellas announced the expansion of its Top Management to include two new positions today, both of which will report directly to Chief Executive Officer Kenji Yasukawa and serve as part of...
Read More
U.S.A.
News / Corporate
Astellas' XOSPATA® (gilteritinib) Receives Conditional Approval by China's National Medical Products Administration for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that the China National Medical Products Administration (NMPA) has granted conditional...
Read More

Jan, 2021

U.S.A.
News / Corporate
Astellas Achieves 100% Score on Corporate Equality Index for Seventh Consecutive Year
For the seventh consecutive year, Astellas has achieved a perfect score on the Human Rights Campaign Foundation's (HRC) annual Corporate Equality Index (the Index). The Index evaluates...
Read More

Dec, 2020

U.S.A.
News / Corporate
Astellas and MBC BioLabs Announce Winners of Golden Ticket Competition to Support Biotech Start-ups Accelerate Early Drug Discovery and Innovation
Astellas Venture Management (President: Kazunori Maruyama, Ph.D, "AVM"), a wholly-owned venture capital subsidiary of Astellas Pharma Inc. and Mission Bay Capital BioLabs ("MBC BioLabs"), a...
Read More